Heparan sulfate proteoglycan and heparin-like glycosaminoglycan (HSPG/HLGAG)

Heparan sulfate proteoglycans (HSPGs) and heparin-like glycosaminoglycans (HLGAGs) are complex carbohydrates and glycoproteins found ubiquitously on cell surfaces and within the extracellular matrix. They serve as essential scaffolds that regulate the bioactivity of numerous proteins, including growth factors, chemokines, and morphogens, thereby influencing cell signaling, adhesion, and tissue development (Source: NIH, PubMed). In clinical medicine, these molecules are primary targets for anticoagulant therapy, where heparin and its derivatives bind to antithrombin to accelerate the inhibition of thrombin and Factor Xa (Source: StatPearls). Beyond hematology, HSPGs are critical in oncology and virology, as they facilitate tumor angiogenesis and serve as attachment receptors for various pathogens, including SARS-CoV-2 and herpes simplex virus (Source: Nature, PubMed). Therapeutic strategies include the use of heparin mimetics and heparanase inhibitors to block these pathological interactions in cancer and inflammatory diseases. However, the ubiquity of HSPGs across various tissues presents significant challenges in achieving tissue-specific targeting without inducing systemic side effects such as hemorrhage (Source: Journal of Biological Chemistry).

Other names

HSPGsHeparin-like GAGsCell surface proteoglycansExtracellular matrix proteoglycansSyndecansGlypicansPerlecansAgrinSerglycin

Drugs targeting these molecules typically act by mimicking or competing with endogenous glycosaminoglycan chains to modulate protein-protein interactions, such as potentiating antithrombin III to inhibit coagulation factors or blocking viral and growth factor binding to cell surfaces.